Related references
Note: Only part of the references are listed.FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Elaine Chang et al.
CLINICAL CANCER RESEARCH (2021)
Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report
Shamika Robinson et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2020)
Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review
Nolan J. Maloney et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy
Andrew Hwang et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature
Ruojun Wang et al.
DERMATOLOGIC THERAPY (2019)
A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis
Qin Xiang Ng et al.
JOURNAL OF INFLAMMATION RESEARCH (2018)
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Marianne Lerch et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis A Systematic Review and Meta-analysis
Stefanie Zimmermann et al.
JAMA DERMATOLOGY (2017)
Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults
Derek Y. Hsu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis
Liang-ping Ye et al.
PLOS ONE (2016)
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis – A Comprehensive Review and Guide to Therapy. I. Systemic Disease
Sahar Kohanim et al.
Ocular Surface (2015)
Recurrence and Mortality Following Severe Cutaneous Adverse Reactions
Yaron Finkelstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Increased frequencies of Th17 cells in drug eruptions
Toshiharu Fujiyama et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2014)
Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis
Yuichi Teraki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
SCORTEN: A severity-of-illness score for toxic epidermal necrolysis
S Bastuji-Garin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
